A set of 17 novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain were synthesized and evaluated for their antibacterial activities, which the aryltetrazolyl group was selected to replace the hetero-aryl moiety of the side chain in telithromycin for designing new compounds. The synthesis of aryltetrazolyl alkylamines was reported in detail. The antibacterial activities of new ketolides were evaluated against a number of pathogens including macrolide-resistant organisms by using telithromycin as the reference. Many of the evaluated compounds exhibited remarkable activities against both erythromycinsusceptible and erythromycin-resistant organisms such as Staphylococcus aureus (except S. aureus AD-08), Pseudomonas aeruginosa and Escherichia coli. Among these, the compound 11e exhibited excellent antibacterial potency against all the strains in comparison with others.
INTRODUCTION
The macrolide antibiotic erythromycin A has been widely used to treat respiratory, skin and soft tissue infections for almost 60 years. In order to overcome the problems associated with acid instability of erythromycin A, 1,2 the second generation of macrolides, including clarithromycin and azithromycin have been developed and used clinically in recent decades. 3, 4 These compounds displayed better pharmacokinetic properties and a broader spectrum of antibacterial activity.
The widespread use of these drugs resulted in macrolide resistance in many pathogenic strains. The primary mechanisms of resistance are mediated by erm-encoded methylation of 23S ribosomal RNA and mef-encoded efflux. [5] [6] [7] To overcome the growing problems of macrolide resistance, great efforts have been made to discover novel macrolides. The kelolides, including telithromycin ( Figure 1 ) and cethromycin (ABT-773), [8] [9] [10] [11] [12] which displayed improved activities against macrolide-resistant pathogens such as Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus aureus (S. aureus), were developed. Both telithromycin and cethromycin share the same key structure features, including 3-keto group, 11,12-cyclic carbamate and a proper hetero-arylalkyl side chain, which is responsible for binding to the 23S ribosomal RNA of bacteria. 13 To develop novel potent ketolides, a variety of structural modifications of the ketolide core skeleton have been carried out. Recently, many ketolide derivatives such as 6-O-alkyl ketolides, [14] [15] [16] [17] [18] [19] 9 -oxime macrolides, [20] [21] [22] [23] [24] [25] 11,12-cyclic carbamate ketolides, [26] [27] [28] [29] [30] [31] [32] 13 -substituents ketolides and 6,11-bridged ketolides [33] [34] [35] with excellent activities toward numerous macrolide-resistant pathogens were obtained. Herein, we described the synthesis and in vitro biological evaluation of a set of novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain. All new derivatives were tested for their antibacterial activities against a number of strains such as S. aureus, Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli). The results will be useful for future design and development of other ketolides.
In our previous work, 3D-QSAR studies on a set of ketolides and their antibacterial activities were carried out. 36 The structure-activity relationship revealed by CoMFA and CoMSIA models indicated that the hydrophilic group at the first heterocyclic ring of side chain in ketolides would increase the potency (Figure 2 ). In an effort to find novel ketolides with extended antibacterial spectrum and improved activity, we designed the novel derivatives by replacing the imidazole ring in telithromycin with a more hydrophilic tetrazole ring.
Tetrazole is a very important pharmacophore skeleton, and is regarded as a bio-isostere of carboxylic group, 37 or a peptide bond. 38 The tetrazole is frequently employed in the lead optimization of ethical drug candidates. The tetrazole-containing compounds were found in various drugs such as matrixmetalloproteinase (MMP) inhibitors, 39 monoamine oxidase B inhibitors, 40 antibacterial, antifungal and antiproliferative agents. 41 This evoked us to develop novel ketolides containing tetrazole group with the hope that they could improve their potencies against susceptible and resistant pathogens. These designed ketolides were new compounds bearing an aryltetrazolyl-substituted alkyl side chain and with varying alkyl length.
RESULTS

Chemistry
In this study, 5-aryl-tetrazolyl alkylamines were prepared as side chain compounds for the first time (Scheme 1). Starting from aromatic nitriles or aromatic aldehydes, the 5-aryl tetrazoles were prepared by (2+3) cycloaddition of nitriles and azides according to the literature procedure. 40, [42] [43] [44] A process similar to Gabriel reaction was applied to achieve 5-aryl-tetrazolyl alkylamines. The N-alkylation on tetrazoles 3 were carried out with N-(3-bromopropyl) phthalimide, N-(4-bromobutyl) phthalimide or N-(5-bromopently) phthalimide to get 4, which were then hydrazinolyzed to produce amines 5.
It was found that when 5-(pyridin-2-yl) tetrazole (3a) was used as a substrate for N-alkylation, a mixture of N1-substituted compounds (4a, 4e and 4i) and N2-substituted products (4b, 4f and 4j) were obtained in different molar ratio (Scheme 2). The possible mechanism was illustrated in Scheme 3. In general, there was equilibrium between 5-pyridinyl-2H-tetrazoles and 5-pyridinyl-1H-tetrazoles. When the 5-(pyridine-2-yl)-tetrazole acted as a substrate, the yielded 1H-tetrazole can be stabilized by forming intramolecular hydrogen bond, therefore, two isomers of 5-(pyridine-2-yl)-tetrazole are present in the same system. Meanwhile, when they reacted with alkylating agents, two N-alkylation products were obtained. As there are not intramolecular hydrogen bonds in 5-(pyridine-3-yl)-tetrazole and 5-(pyridine-4-yl)-tetrazole, they mainly yielded 2H-tetrazole. The products of N-alkylation are predominance in N2-substituted compounds.
A series of C-11,12 cyclic carbamate ketolide derivatives (11aBq) were prepared via eight steps from clarithromycin by following the similar synthesis procedures of telithromycin. 45, 46 Synthesis route was shown in Scheme 4. Clarithromycin was treated with diluted acid to accomplish cleavage of cladinose, which afforded 3-O-decladinosyl-6-O-methylerythromycin. Protection of 2¢-OH of 3-O-decladinosyl-6-O-erythromycin was achieved by using benzoic anhydride to provide compound 6. Formation of 11,12-cyclic carbonate of derivative 7 was carried out with triphosgene in a mixture of CH 2 Cl 2 and pyridine at 0 1C. The resulting derivative 7 was oxidized by pyridinium chlorochromate to yield the ketolide 8. Treatment of 8 with 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU) in acetone allowed formation of 9. Deprotonation of the C-12 hydroxyl of 9 with sodium hydride and carbonyldiimidazole yielded the C-12 imidazoyl carbamate 10. Finally, compound 10 on reaction with an excess of side chain 5-aryl-tetrazolyl alkylamine, and then deprotection of the benzonate by refluxing in methanol yielded the final ketolide 11. The structures of the novel ketolide derivatives (11a-q) were displayed in Figure 3 .
Antibacterial activity
All of the synthesized ketolides, taking erythromycin, clarithromycin and telithromycin as reference compounds, were tested for in vitro antibacterial activity against six strains of S. aureus, three strain of P. aeruginosa and two strains of E. coli. Their MICs were determined by the broth microdillution method recommended by the National Committee for Clinical Laboratory Standards 47 and listed in Table 1 . The strains included three erythromycin-susceptible strains of S. aureus ATCC 29213, 6538p and 26001, three erythromycinresistant clinical isolates of S. aureus 5676, 5677 and AD-08, and two strains of P. aeruginosa ATCC 27853 and 9027, a clinical isolate of P. aeruginosa 1317, as well as E. coli ATCC 8739 and 25922.
The tabulated results revealed that erythromycin and clarithromycin were potent against erythromycin-susceptible strains and inactive toward all the resistant strains. Some of the evaluated compounds showed potent or equivalent activities compared with that of telithromycin. The novel ketolides that possessed 4-5 carbon atoms alkyl side chain, such as 11e-k, exhibited somewhat increased potencies Electron-withdrawing groups or hydrogen bond do nor groups will improve activity Electron-withdrawing groups will improve activity Figure 2 Structure-activity relationships of ketolides from 3D-QSAR study. 36 Novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain Q-L Song et al toward all of the erythromycin-susceptible S. aureus; 11n, 11p and 11q showed the equivalent potencies compared with telithromycin against the erythromycin-susceptible S. aureus. Compounds 11a, 11e-i, 11n displayed some extent increased potencies against erythromycinresistant S. aureus 5677; 11d, 11j, 11k, 11p, and 11q showed the equivalent potencies compared with telithromycin against S. aureus 5677. Meanwhile, the compound 11n bearing a phenyl-tetrazolyl moiety in the side chain was slightly more potent against S. aureus AD-08. Furthermore, compared with 11b, 11c and 11d, the compound 11a exhibited the improved potencies against both erythromycin-susceptible S. aureus and erythromycin-resistant S. aureus. Some of the novel ketolides were slightly more potent against P. aeruginosa and E. coli. Generally compounds 11a, 11eBh and 11q seemed to be more potent than other tetrazole-containing ketolides toward P. aeruginosa ATCC 27853. Especially the compounds 11e, 11p and 11q showed the equivalent or improved activities compared with telithromycin against P. aeruginosa ATCC 27853 and 9027, and P. aeruginosa 1317. Compounds 11e and 11q also showed the same or improved potencies compared with telithromycin against E. coli strains.
The results indicated that compound 11e was one of the most active compounds, which exhibited excellent activity against both the Gram-positive and Gram-negative pathogens. It could be inferred that introducing the 5-(pyridin-2-yl)-1H-tetrazol-1-yl group as a heterocyclic moiety in the side chain may enhance the antibacterial activity of ketolide.
Conclusions
Seventeen novel ketolides have been synthesized and evaluated for antibacterial activities against Gram-positive and Gram-negative pathogens. All of the synthesized compounds were found to be potent against both erythromycin-susceptible and erythromycin-resistant 5b n = 1; 5f n = 2; 5j n = 3.
4b n = 1; 4f n = 2; 4j n = 3.
Scheme 2 Synthesis of N1-substituted and N2-substituted 5-aryl-tetrazolyl alkylamines. Reagents and condition: (a) NaN 3 , NH 4 Cl, DMF 130
Novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain Q-L Song et al strains. Some of the compounds (for example, 11e-l, 11n, 11p and 11q, having alkyl length side chains with 4-5 carbon atoms) exhibited better or the same inhibitory potencies compared with telithromycin against erythromycin-susceptible strains. Compound 11e showed excellent activity against all the strains but S. aureus AD-08, which inferred that compounds bearing the 5-(pyridin-2-yl)-1H-tetrazol-1-yl group as a heterocyclic moiety in the side chain of ketolides may enhance their antibacterial activities. The results could aid in designing for novel ketolides with desired potencies.
METHODS
General experimental procedures
All reagents and solvents were purchased from commercial sources. Further purification and drying by standard methods were employed when necessary. Clarithromycin and its derivatives were predried azeotropically from benzene. 2-(2H-tetrazol-5-yl) pyridine (3a), 3-(2H-tetrazol-5-yl) pyridine (3b), 4-(2H-tetrazol-5-yl) pyridine (3c), 5-phenyl-2H-tetrazole (3d), 5-(thiophen-2-yl)-2H-tetrazole (3e) and 5-(furan-2-yl)-2H-tetrazole (3f) were prepared according to the literature procedure.
General procedure for the synthesis of compounds 4a-q
To a solution of aryl-tetrazole (3a-f) (5 mmol) in anhydrous N,N-dimethylformamide (DMF) (24 ml) was added K 2 CO 3 (5 mmol) and N-(bromoalkyl)phthalimide (6 mmol). The mixture was heated to 80 1C for 10 h under nitrogen. Then the mixture was poured into ice water (100 ml), and the resulting precipitation was filtered and washed with ice water. The crude product was purified by column chromatography on silica gel using petroleumethyl acetate (1:1) to petroleum-ethyl acetate-dichloromethane (1:1:1), affording compounds 4a-q as a white solid. 
2-(5-(5-(Pyridin-2-yl)-2H-tetrazol-2-yl)pentyl)isoindoline-1,3-dione (4j)
Yield
2-(5-(5-(Pyridin-4-yl)-2H-tetrazol-2-yl)pentyl)isoindoline-1,3-dione (4l)
Yield 92%. 1 
2-(4-(5-(Thiophen-2-yl)-2H-tetrazol-2-yl)butyl)isoindoline-1,3-dione (4p)
Yield 63%. 1 
2-(4-(5-(Furan-2-yl)-2H-tetrazol-2-yl)butyl)isoindoline-1,3-dione (4q)
Yield 85%. 1 
General procedures for the synthesis of compounds 5a-q
To a solution of compound 4a-q (3 mmol) in ethanol (20 ml) and acetonitrile (15 ml) was added hydrazine monohydrate (85%, 6 mmol). The solution was refluxed for 6 h. After cooling to room temperature, the mixture was filtered and washed with ethanol. The filtrate was concentrated in vacuo. To the residue NaOH aqueous solution (2 mol l -1 , 30 ml) was added. Then it was extracted with dichloromethane (30 mlÂ3), washed with brine, dried over Na 2 SO 4 and concentrated in vacuo. The residue was purified by column chromatography on silica gel using dichloromethane:methanol:triethylamine (9:1:0.1) as eluent to give compounds 5a-q as a yellow oil. 
3-(5-(Pyridin-2-yl)-1H-tetrazol-1-yl)propylamine (5a)
4-(5-(Pyridin-3-yl)-2H-tetrazol-2-yl)butylamine (5g)
3-O-Descladinosyl-6-O-methyl-2¢-O-benzoyl erythromycin A (6)
Stage a: to a solution of clarithromycin (9.0 g, 12 mmol) in water (100 ml) and ethanol (500 ml) at 0 1C was added HCl (aq) (2 mol l -1 , 21.6 ml) dropwise within 50 min. The solution was stirred at room temperature for 24 h. After 24 h, NaOH (aq) (2 mol l -1 , 120 ml) was added to adjust pH of the solution to 10.5B11.0, then the mixture was stirred for 1 h at 0 1C. The resulted precipitation was filtered, washed with a little water and yielded 3-O-descladinosyl-6-Omethyl-erythromycin A as white solid (6.2 g, 87% Stage b: to a solution of 3-O-descladinosyl-6-O-methyl-erythromycin A (6 g, 10 mmol) in anhydrous CH 2 Cl 2 (25 ml) at 0 o C was added benzoic anhydride (3.8 g, 16 mmol), triethylamine (2.2 ml, 16 mmol) and a sprinkle of 5-dimethylaminopyridine. The solution was stirred for 58 h at room temperature. Cold saturated NaHCO 3 (aq) (20 ml) was added and the mixture was stirred for another 30 min. Then the organic layer was separated and washed with water, brine, dried over Na 2 SO 4 , filtered, the filtrate was concentrated in vacuo, the residue was purified by column chromatography on silica gel using petroleum:acetone:triethylamine (5:1:0.01) as eluent to afford 6 (6.03 g, 86%) as a white solid. 1 
3-O-Descladinosyl-6-O-methyl-cyclic 11,12-carbonate-2¢-O-benzoyl erythromycin A (7)
To a solution of compound 6 (2 g, 2.89 mmol) in CH 2 Cl 2 (27 ml) was added pyridine (1.87 ml, 23.12 mmol), the solution was stirred at 0 1C for 20 min under nitrogen atmosphere. After 20 min, triphosgene (1.03 g, 3.47 mmol) in Novel ketolides bearing an aryltetrazolyl-substituted alkyl side chainCH 2 Cl 2 (5 ml) was added to above solution. The solution was stirred at room temperature for another 7 h. After quenching with cold brine (30 ml) at 0 1C, the organic layer was separated and the aqueous layer was extracted with dichloromethane (20 mlÂ3). The combined organic extracts were washed with brine, dried over Na 2 SO 4, , filtered, the filtrate was concentrated in vacuo, the residue was purified via silica gel column using petroleum:acetone:triethylamine (5:1:0.01) as eluent to afford 7 (1.72 g, 83%) as a white solid. 1 To a solution of compound 8 (0.2 g, 0.28 mmol) in anhydrous dichloromethane (3 ml) was added pyridinium chlorochromate (0.18 g, 0.85 mmol), the solution was stirred for 25 h at room temperature. The reaction was diluted with dichloromethane (5 ml) and washed with saturated NaHCO 3 , brine, dried over Na 2 SO 4 , filtered, the filtrate was concentrated in vacuum, the residue was purified by column chromatography on silica gel using petroleum:acetone:-triethylamine (3:1:0.01) as eluent to afford 8 (0.15 g, 71%) as a white solid. 1 To solution of compound 8 (1.86 g, 2.6 mmol) in acetone (30 ml) was added 1,8-diazabicyclo [5.4 .0]undec-7-ene (0.99 g, 6.5 mmol), the solution was stirred at 60 1C for 5 h. On concentrating and drying in vacuum, the residue was dissolved in dichloromethane and washed with brine, dried over Na 2 SO 4 , filtered, the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel using petroleum:acetone:triethylamine (6:1:0.01) as eluent to afford 9 (1.71 g, 98 %) as a white solid. 1 
10,11-
To a solution of compound 9 (2 g, 3 mmol) in DMF (15 ml) was added sodium hydride (60% dispersion in mineral oil 0.25 g, 6 mmol), the solution was stirred at À10 1C under nitrogen atmosphere. After stirring for 30 min, a solution of CDI (1.56 g, 9 mmol) in DMF (15 ml) was added and stirred for another 2 h at -5B-10 1C. Then the mixture was warmed to 0 1C, ice water (50 ml) was added cautiously to quench the excess sodium hydride. The precipitation was filtered, washed with a little water twice. The material was diluted with dichloromethane and washed with brine, dried over Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The crude product was purified by column chromatography on silica gel using petroleum:acetone:triethylamine (6:1:0.01) as eluent to afford 10 (2.05 g, 90%) as a white solid. 1 
General procedures for the synthesis of compounds 11a-q
To a solution of compound 10 (0.26 mmol) in acetonitrile (1 ml) was added compound (5a-q) (0.53 mmol), the solution was heated in a 55 1C oil bath and stirred for 24 h. On quenching with ice water (5 ml), the mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , and brine, dried over Na 2 SO 4 . Filtered, the filtrate was concentrated in vacuo. After adding methanol (5 ml) to the crude material, the solution was stirred at 60 1C for another 25 h. On concentrating, the crude product was purified by column chromatography on silica gel using petroleum:acetone:triethylamine (5:1:0.01) as eluent to afford compounds 11a-q as a white solid.
Compound 11a
Yield 58%. 1 
